This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Cancer Stocks Focus of ASCO Abstract Release

BOSTON ( TheStreet) -- Investors got their first look at thousands of cancer drug research abstracts released Wednesday night by the American Society of Clinical Oncology (ASCO) in advance of its closely watched annual meeting.

Among the most significant cancer drug data unveiled for the first time Wednesday night came from phase III studies conducted by Incyte (INCY - Get Report) and Ariad Pharmaceuticals (ARIA - Get Report). New disclosures of clinical data were also available from Exelixis (EXEL - Get Report), Onyx Pharmaceuticals (ONXX), AstraZeneca (AZN), Celgene (CELG - Get Report) and Nektar Therapeutics (NKTR - Get Report).

The ASCO annual meeting runs June 3-7 and brings together cancer drug researchers from all over the world to discuss and present new clinical data aimed at treating -- and maybe one day curing -- cancer. Wednesday's release of research abstracts -- short, preliminary summaries of efficacy and safety data from cancer drug clinical trials -- serves as a warm-up for the big event next month.

The ASCO abstract release is also a closely watched event for Wall Street because the revelation of new cancer drug data often has a significant effect on biotech and drug stocks. Many so-called "ASCO stocks" -- particularly biotech stocks with small market caps -- have already started to move higher weeks before the ASCO confab even gets started.

While ASCO whet investors' appetite for cancer drug data Wednesday, the medical society did reserve some of the most impactful research for a more high-profile release at the meeting itself. This includes overall survival data from two separate phase III studies of skin cancer drugs from Bristol-Myers Squibb (BMY) and Roche that will be presented at the meeting's plenary session. Pfizer (PFE) will also present for the first time results from a phase III study of a new kidney cancer drug at the ASCO meeting in June.

Some of the most highly anticipated clinical data at this year's ASCO conference comes from Incyte, which along with partner Novartis (NVS), is developing a drug known as ruxolitinib for the treatment of myelofibrosis, a cancer in which abnormal bone marrow stem cells produce scar tissue that replaces healthy marrow. Patients with myelofibrosis suffer from anemia and enlarged spleens.

Incyte previously announced positive results from a U.S. phase III study of ruxolitinib in myelofibrosis last December, but new data from the so-called COMFORT-I study were released for the first time in an ASCO abstract.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ONXX $0.00 0.00%
ARIA $8.03 -1.23%
BMY $62.30 2.27%
CELG $120.31 -1.00%
EXEL $3.09 5.46%


DOW 18,288.63 +155.93 0.86%
S&P 500 2,117.39 +12.89 0.61%
NASDAQ 5,008.0960 +44.5690 0.90%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs